Acute Kidney Injury Clinical Trials in San Francisco, California

6 studies are recruiting for acute kidney injury in San Francisco, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Neutrophil and Monocyte Deactivation Via the SeLective CytopheretIc Device - A Randomized Clinical Trial in Acute Kidney Injury

   This randomized, controlled, pivotal study is intended to determine whether up to ten sequential 24-hour treatments with the Selective Cytopheretic Device (SCD) will improve survival in patients with Acute Kidney Injury (AKI) requiring continuous kidney replacement therapy (CKRT) when compared to C…

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of California San Francisco, San Francisco, California

   Locations

   36 in total

   Run by

   SeaStar Medical

   See if you can join NCT05758077 on ClinicalTrials.gov

2. A Prompt REstart Study of Renin-Angiotensin System Inhibitors After Acute Kidney Injury

   The goal of this pilot clinical trial is to learn if early restart of renin-angiotensin system inhibitor (RASi) medications is feasible and well-tolerated in hospitalized patients with acute kidney injury (AKI). Researchers will compare early RASi restart to usual care. Study participants will rest…

   Stage

   Phase 4

   Ages

   18 and older

   Site

   University of California, San Francisco, San Francisco, California

   Run by

   University of California, San Francisco

   See if you can join NCT07734636 on ClinicalTrials.gov

3. QUELIMMUNE (SCD-PED) PediAtric SurVeillance REgistry

   QUELIMMUNE is FDA-approved under an HDE for the treatment of pediatric patients (weight ≥10kg and age ≤22 years) with AKI due to sepsis or a septic condition on antibiotic therapy and requiring RRT. The purpose of this surveillance registry is to prospectively collect safety data among all patients…

   Stage

   Not phased

   Ages

   Up to 22

   Site

   UCSF Benioff Children's, San Francisco, California

   Locations

   15 in total

   Run by

   SeaStar Medical

   See if you can join NCT06517810 on ClinicalTrials.gov

4. Allogeneic HB-adMSCs vs Placebo for the Treatment of Acute Kidney Injury

   This study aims to investigate, through the collection of valid scientific evidence necessary to determine safety and effectiveness, the potential use of Allogeneic Hope Biosciences Adipose-derived Mesenchymal Stem Cells (HB-adMSCs) to prevent progression of trauma-induced Acute Kidney Injury (AKI).

   Stage

   Phase 1

   Ages

   18 to 75

   Site

   University of California, San Francisco, San Francisco, California

   Locations

   3 in total

   Run by

   Hope Biosciences LLC

   See if you can join NCT06654193 on ClinicalTrials.gov

5. NAD+ Augmentation in Cardiac Surgery Associated Myocardial Injury Trial

   A Randomized, Double-blind, placebo-controlled Trial to Evaluate the Efficacy of Oral Nam for the Prevention of Acute Kidney Injury in Patients Undergoing On-Pump Cardiac Surgery

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Kaiser Permanente San Francisco Medical Center, San Francisco, California

   Run by

   Kaiser Permanente

   See if you can join NCT04750616 on ClinicalTrials.gov

6. Physiologic Signals and Signatures With the Accuryn Monitoring System - The Accuryn Registry

   The Accuryn Registry Study is an open-ended, global, multi-center, retrospective and prospective, single-arm data collection study with an FDA cleared device. The target population are cardiovascular surgery patients. Physiologic data measurements will be collected from enrolled subjects using elec…

   Stage

   Not phased

   Ages

   18 and older

   Site

   San Francisco VA Medical Center, San Francisco, California

   Locations

   9 in total

   Run by

   Potrero Medical

   See if you can join NCT04669548 on ClinicalTrials.gov